[go: up one dir, main page]

FI933304L - Oralt givna laekemedel foer behandling av centrala dopaminbristtillstaond - Google Patents

Oralt givna laekemedel foer behandling av centrala dopaminbristtillstaond Download PDF

Info

Publication number
FI933304L
FI933304L FI933304A FI933304A FI933304L FI 933304 L FI933304 L FI 933304L FI 933304 A FI933304 A FI 933304A FI 933304 A FI933304 A FI 933304A FI 933304 L FI933304 L FI 933304L
Authority
FI
Finland
Prior art keywords
oralt
givna
dopaminbristtilllstaond
centrala
laekemedel
Prior art date
Application number
FI933304A
Other languages
English (en)
Other versions
FI933304A0 (fi
FI101040B (fi
Inventor
Udo Wenzel
Guenther Weber
Juergen Metzner
Alfred Daerr
Sabine Freitag
Frank-Ulrich Floether
Frank-Michael Albert
Margit Haase
Edith Leistner
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Publication of FI933304L publication Critical patent/FI933304L/fi
Publication of FI933304A0 publication Critical patent/FI933304A0/fi
Application granted granted Critical
Publication of FI101040B publication Critical patent/FI101040B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI933304A 1991-01-23 1993-07-22 Menetelmä sentraalisten dopamiininpuutostilojen hoitoon tarkoitetun, p eroraalisesti annettavan lääkemuodon valmistamiseksi FI101040B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4101873 1991-01-23
DE4101873A DE4101873C2 (de) 1991-01-23 1991-01-23 Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
DE9200043 1992-01-23
PCT/DE1992/000043 WO1992012710A1 (de) 1991-01-23 1992-01-23 Peroral applizierbare arzneiform zur behandlung zentraler dopaminmangelzustände

Publications (3)

Publication Number Publication Date
FI933304L true FI933304L (fi) 1993-07-22
FI933304A0 FI933304A0 (fi) 1993-07-22
FI101040B FI101040B (fi) 1998-04-15

Family

ID=6423528

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933304A FI101040B (fi) 1991-01-23 1993-07-22 Menetelmä sentraalisten dopamiininpuutostilojen hoitoon tarkoitetun, p eroraalisesti annettavan lääkemuodon valmistamiseksi

Country Status (22)

Country Link
US (1) US5532274A (fi)
EP (1) EP0568577B1 (fi)
JP (1) JP3382940B2 (fi)
AT (1) ATE147264T1 (fi)
AU (1) AU658171B2 (fi)
BG (1) BG61677B1 (fi)
CA (1) CA2101164C (fi)
CZ (1) CZ280847B6 (fi)
DE (2) DE4101873C2 (fi)
DK (1) DK0568577T3 (fi)
EE (1) EE03016B1 (fi)
ES (1) ES2098496T3 (fi)
FI (1) FI101040B (fi)
GR (1) GR3022993T3 (fi)
LT (1) LT3659B (fi)
LV (1) LV11103B (fi)
NO (1) NO304638B1 (fi)
RO (1) RO114737B1 (fi)
RU (1) RU2114619C1 (fi)
SK (1) SK278736B6 (fi)
UA (1) UA27848C2 (fi)
WO (1) WO1992012710A1 (fi)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
RU2173150C1 (ru) * 2000-06-27 2001-09-10 Васильев Виталий Николаевич Фармацевтическая композиция для биокоррекции симпатико-адреналовой системы
US6531153B2 (en) 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
BR0212951A (pt) * 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas
EP1560569A4 (en) * 2002-10-11 2006-03-22 Depomed Dev Ltd GASTRORETENTIVE LEVODOPA DELIVERY FORM
US8815950B2 (en) * 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
JP5160786B2 (ja) * 2003-08-29 2013-03-13 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
EP1751087B1 (en) * 2004-06-04 2012-06-27 XenoPort, Inc. Levodopa derivatives, and compositions and uses thereof
RU2440100C2 (ru) * 2005-03-28 2012-01-20 Орексо Аб Новые фармацевтические композиции, полезные в лечении болезни паркинсона
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
JP5783725B2 (ja) 2007-12-28 2015-09-24 インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． レボドパの放出制御製剤及びその使用
EP2233131A1 (en) * 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
JP6694564B1 (ja) * 2018-11-13 2020-05-13 日本酢ビ・ポバール株式会社 結合剤
CN112955136A (zh) * 2018-11-13 2021-06-11 日本瓦姆&珀巴尔株式会社 粘结剂
JP6695013B1 (ja) * 2018-11-13 2020-05-20 日本酢ビ・ポバール株式会社 結合剤
EP3881838A4 (en) * 2018-11-13 2022-08-17 Japan Vam & Poval Co., Ltd. ADHESIVE
US20230148062A1 (en) * 2020-04-10 2023-05-11 Japan Vam & Poval Co., Ltd. Binder
WO2022107856A1 (ja) * 2020-11-19 2022-05-27 旭化成株式会社 多孔質膜
WO2022140448A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE631201C (de) * 1932-08-07 1936-06-16 Chemische Forschungs Gmbh Traegerstoff fuer Arzneimittel
DE748317C (de) * 1941-08-17 1944-12-19 Wacker Chemie Gmbh Verfahren zur Herstellung in Wasser zerfallender Faeden, Filme, Baender, Schlaeuche u. dgl. aus unvollstaendig verseiften Polyvinylalkoholen
US3584113A (en) 1967-08-31 1971-06-08 Eisai Co Ltd Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (nl) * 1968-10-01 1976-05-17 Merck & Co Inc Werkwijze voor het bereiden van farmaceutische preparaten, alsmede de door toepassing daarvan verkregen gevormde voortbrengselen.
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en) 1979-04-26 1985-10-16 Merrell Toraude & Co Alpha-halomethylaminoacids
DE3042916A1 (de) * 1979-06-01 1982-07-01 Joachim 7440 Nürtingen Dudzik Tablette
CA1218604A (en) * 1981-07-08 1987-03-03 Alec D. Keith Trinitroglycerol sustained release vehicles and preparations therefrom
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
AU608891B2 (en) * 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
DE3841955A1 (de) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets
EP0324947B2 (de) * 1987-12-31 1997-08-20 ASTA Medica Aktiengesellschaft Synergistische Kombination von Decarboxylasehemmern und L-Dopa-Pellets

Also Published As

Publication number Publication date
EE03016B1 (et) 1997-08-15
JP3382940B2 (ja) 2003-03-04
GR3022993T3 (en) 1997-07-30
CA2101164A1 (fr) 1992-07-24
BG97894A (bg) 1994-04-29
DE59207852D1 (de) 1997-02-20
NO932522L (no) 1993-07-09
LTIP555A (en) 1994-11-25
RO114737B1 (ro) 1999-07-30
AU1186892A (en) 1992-08-27
LV11103B (en) 1996-06-20
AU658171B2 (en) 1995-04-06
UA27848C2 (uk) 2000-10-16
CZ369292A3 (en) 1993-09-15
EP0568577A1 (de) 1993-11-10
CZ280847B6 (cs) 1996-04-17
ES2098496T3 (es) 1997-05-01
LV11103A (lv) 1996-04-20
LT3659B (en) 1996-01-25
US5532274A (en) 1996-07-02
JPH06504543A (ja) 1994-05-26
DE4101873A1 (de) 1992-07-30
SK369292A3 (en) 1998-02-04
DE4101873C2 (de) 1993-12-09
WO1992012710A1 (de) 1992-08-06
FI933304A0 (fi) 1993-07-22
BG61677B1 (bg) 1998-03-31
CA2101164C (fr) 2001-04-24
DK0568577T3 (da) 1997-06-30
SK278736B6 (sk) 1998-02-04
FI101040B (fi) 1998-04-15
ATE147264T1 (de) 1997-01-15
RU2114619C1 (ru) 1998-07-10
EP0568577B1 (de) 1997-01-08
NO932522D0 (no) 1993-07-09
NO304638B1 (no) 1999-01-25

Similar Documents

Publication Publication Date Title
FI912605L (fi) Av skilda moduler hopsaettbar radiotelefon
FI920875L (fi) Foerfarande foer avfaergning av avfallspapper
FI933304L (fi) Oralt givna laekemedel foer behandling av centrala dopaminbristtillstaond
FI920742L (fi) Foebaettrad aktovering av rekombinantproteiner
FI920861L (fi) Foerfarande foer framstaellning av antitrombiniska polypeptider
FI921202L (fi) Foerfarande foer instaellning av rasterpunktstorleken foer en offset-rotationstryckmaskin
FI920993L (fi) Foerfarande foer framstaellning av galliumfoereningar
FI920877L (fi) Foerfarande foer utvinning av syre
FI915201L (fi) Arrangemang foer styrning av en ekoslaeckare
FI920830L (fi) Foerfarande foer delignifiering av cellulosahaltiga raomaterialer
FI921150L (fi) Foerfarande foer framstaellning av humektant
FI921550L (fi) Foerfarande foer belaeggning av en fiberfoerstaerkt plastkropp
FI921155A7 (fi) Anordning foer avlaegsning av gasvaetskeblandningar fraon elektrolysceller
FI88701B (fi) Foerfarande foer producering av vaeteperoxid
FI920853L (fi) Anordning foer fjaerrtestning av ledningar
FI914586L (fi) Foerfarande foer foerminskning av asklasten av en cellufabriks pannanlaeggning
FI920656A7 (fi) Foerfarande foer framstaellning av disubstituerade urea- och tioureaderivat
FI921069L (fi) Foerfarande foer diastereoselektiv reduktiv pinakolkoppling av homokirala a-aminoaldehyder
FI912347L (fi) Grovinstaellning av kanalfrekvensen
FI920422L (fi) Foerfarande foer ytfoerening av kiselhalvledarskivor
FI920831L (fi) Foerfarande foer delignifiering av cellulosahaltiga raomaterialer
FI920926L (fi) Foerfarande foer foerbaettring av stabiliteten foer hoegalkaliska proteaser
FI912871L (fi) Foerfarande foer boejning av glasskivor
FI88635C (fi) Anordning foer fraesning av jord
FI920823L (fi) Foerfarande foer framstaellning av fettsyrahalogenid